- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT03283020
Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume
Opioid-Induced Swallowing Dysfunction - The Impact of Bolus Volume: a Randomized, Double-Blind Study in Healthy Volunteers
Studieoversikt
Status
Intervensjon / Behandling
Detaljert beskrivelse
Monitored anesthesia care (MAC) is commonly applied in modern perioperative care and means that minor surgical procedures are accomplished in awake patients using local anesthesia and light sedation. MAC has many advantages compared to general anesthesia; the recovery time after anesthesia is shorter and risk for postoperative nausea is lower to mention some. However, the patient is spontaneously breathing and the airway is not protected by an endotracheal tube which potentially increases risk of pulmonary aspiration. Pulmonary aspiration, that is inhalation of stomach and/or pharyngeal contents into the lungs, is a severe anesthesia-related complication and can in worst case lead to pneumonia and even death. Intact swallowing function is crucial in avoiding aspiration and how sedatives and analgesic agents used during MAC influence swallowing function is not fully understood.
Pharyngeal function during bolus swallowing is measured by combined high resolution impedance manometry (HRIM). The HRIM catheter is inserted through the nose in such a way that sensors straddle the entire pharynx and esophagus with the distal catheter tip in the stomach. Dynamic pressure changes and flow can be detected during swallowing and data registered by HRIM are analysed using purpose-designed software, AIM analysis (automated impedance manometry analysis). AIM analysis derives pressure flow variables which describe different physiological events like bolus timing and bolus distension in the pharynx and the esophagus during swallowing. A Swallow Risk Index value, quantifying risk of deglutitive aspiration, can also be defined.
The aim of the study is to evaluate impact of different bolus volumes on remifentanil-induced swallowing dysfunction in healthy volunteers. The study will clarify underlying mechanisms (central vs. peripheral effects) of remifentanil-induced swallowing dysfunction. Furthermore, whether swallowing tasks can be done safer during sedation by altering bolus volumes will be revealed. In addition to bolus volume, different bolus viscosities will be tested. It is shown that higher bolus viscosity diminishes misdirected swallows in dysphagic patients and higher bolus viscosity may possibly counteracts the swallowing dysfunction induced by remifentanil. Moreover, if MNTX reverses the remifentanil-induced effects on swallowing, then this would suggest a dominant peripherally mediated mechanism. Our aim is also to evaluate impact of remifentanil exposure on esophageal motility and impact of methylnaltrexone alone on swallowing function.
20 healthy volunteers will be studied on two different occasions approximately one week apart. In a randomized order volunteers will receive intravenous infusion of remifentanil and an intravenous injection of MNTX on one occasion, and placebo (normal saline) infusion and an intravenous injection of MNTX on the other occasion. Blood samples are obtained for plasma concentration determination of the study drug and sedation levels are assessed during study drug exposure.
Studietype
Registrering (Forventet)
Fase
- Fase 4
Kontakter og plasseringer
Studiekontakt
- Navn: Johanna Savilampi, MD, PhD
- Telefonnummer: +46196020266
- E-post: johanna.savilampi@regionorebrolan.se
Studiesteder
-
-
-
Örebro, Sverige, 70185
- Rekruttering
- Department of Anaesthesiology and Intensive Care, Örebro University Hospital
-
Ta kontakt med:
- Johanna Savilampi, Phd
- E-post: johanna.savilampi@regionorebrolan.se
-
Ta kontakt med:
- Per Cajander, MD
- E-post: per.cajander@regionorebrolan.se
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- ≥ 18 - ≤ 40 year old healthy volunteers from both sexes.
- Have signed and dated Informed Consent.
- Willing and able to comply with the protocol for the duration of the trial.
Exclusion Criteria:
- Anamnesis of pharyngoesophageal dysfunction.
- Known or history of gastrointestinal, severe cardiac, pulmonary or neurological disease
- Ongoing medication that may affect upper gastrointestinal tract, larynx or lower airway.
- Allergies to or history of reaction to remifentanil, fentanyl analogues or dexmedetomidine.
- Pregnancy or breast feeding
- BMI > 30
- Smoking
- Previous participation in a medicinal clinical trial during the last year where an opioid has been used or have during the last 30 days participated in any other medicinal clinical trial or in a trial where follow-up is not completed.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Dobbelt
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Aktiv komparator: RemifentanilMNTX
Volunteers are given an intravenous infusion with remifentanil, with an effect-site target concentration of 3 ng/ml via a target-controlled infusion (TCI) pump.
After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
|
Remifentanil infusion TCI 3 ng/ml, Methylnaltrexone injection 0.3 mg/kg
Andre navn:
|
Aktiv komparator: PlaceboMNTX
Volunteers are given an intravenous infusion with saline 0,9%.
After a series of swallowing tests an intravenous injection of methylnaltrexone of 0,3 mg/kg is given.
|
Placebo (NaCl 0.9%) TCI infusion, Methylnaltrexone injection 0.3 mg/kg
Andre navn:
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pressure Flow pharyngeal variables, 10 ml vs 20 ml bolus
Tidsramme: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during remifentanil exposure between bolus volumes of 10 ml and 20 ml compared to placebo.
|
Up to 60 minutes
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
Pressure Flow pharyngeal variables, liquid vs semisolid bolus
Tidsramme: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during remifentanil exposure between liquid and semisolid boluses compared to placebo
|
Up to 60 minutes
|
Pressure Flow pharyngeal variables, remifentanil before vs after methylnaltrexone
Tidsramme: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
|
Up to 60 minutes
|
Pressure Flow pharyngeal variables, placebo before vs after methylnaltrexone
Tidsramme: Up to 60 minutes
|
Difference in pharyngeal pressure flow variables during placebo infusion before and after methylnaltrexone administration.
|
Up to 60 minutes
|
Pressure Flow esophageal motility variables, 10 ml vs 20 ml bolus
Tidsramme: Up to 60 minutes
|
Difference in variables of esophageal motility between different bolus volumes during remifentanil exposure compared to placebo.
|
Up to 60 minutes
|
Pressure Flow esophageal motility variables, liquid vs semisolid bolus
Tidsramme: Up to 60 minutes
|
Difference in variables of esophageal motility between liquid and semisolid boluses during remifentanil exposure compared to placebo.
|
Up to 60 minutes
|
Pressure Flow esophageal motility variables, remifentanil before vs after methylnaltrexone
Tidsramme: Up to 60 minutes
|
Difference in variables of esophageal motility during remifentanil exposure before and after methylnaltrexone administration compared to placebo.
|
Up to 60 minutes
|
Pressure Flow esophageal motility variables, placebo before vs after methylnaltrexone
Tidsramme: Up to 60 minutes
|
Difference in variables of esophageal motility during placebo infusion before and after methylnaltrexone administration.
|
Up to 60 minutes
|
Samarbeidspartnere og etterforskere
Sponsor
Etterforskere
- Hovedetterforsker: Johanna Savilampi, MD, PhD, University Hospital in Örebro
Studierekorddatoer
Studer hoveddatoer
Studiestart (Faktiske)
Primær fullføring (Forventet)
Studiet fullført (Forventet)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- JS006
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Faryngeal dysfunksjon
-
Assiut UniversityUkjentPacemaker Lead DysfunctionItalia
-
University of ChicagoFullførtICD | Enhetsfeil | Pacemaker Lead DysfunctionForente stater
-
Nova Scotia Health AuthorityUkjentPatulous Eustachian Tube DysfunctionCanada
-
Radboud University Medical CenterFullførtSepsis | Betennelse | Endotoksemi | Multi Organ Dysfunction SyndromeNederland
-
International Centre for Diarrhoeal Disease Research...Washington University School of Medicine; Bangladesh Specialized Hospital; Sheikh Russel National Gastroliver Institute & HospitalRekrutteringUnderernæring | Tarmmikrobiota | Environmental Enteric Dysfunction (EED) | Kvinner i reproduktiv alder | Mikrobiota rettet komplementær mat (MDCF)Bangladesh
-
Medical University of South CarolinaFullførtSphincter of Oddi DysfunctionForente stater
-
Nationwide Children's HospitalEunice Kennedy Shriver National Institute of Child Health and Human Development...RekrutteringPediatrisk Sepsis-indusert Multiple Organ Dysfunction SyndromeForente stater
-
Cedars-Sinai Medical CenterRekruttering
-
Medical University of South CarolinaNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)FullførtSphincter of Oddi DysfunctionForente stater
-
Radboud University Medical CenterFullførtSepsis | Betennelse | Endotoksemi | Multi Organ Dysfunction SyndromeNederland